Sunagawa O, Shinzato Y, Touma T, Tomori M, Fukiyama K (May 2000). “Differences between coronary hyperresponsiveness to ergonovine and vasospastic angina”. 《Japanese Heart Journal》 41 (3): 257–268. doi:10.1536/jhj.41.257. PMID10987346.
Ott J, Neely P (1980). “Entheogenic (hallucinogenic) effects of methylergonovine”. 《Journal of Psychedelic Drugs》 12 (2): 165–166. doi:10.1080/02791072.1980.10471568. PMID7420432.
Cavero I, Guillon JM (2014). “Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy”. 《Journal of Pharmacological and Toxicological Methods》 69 (2): 150–161. doi:10.1016/j.vascn.2013.12.004. PMID24361689.
drugs.com
“Ergonovine Maleate”. The American Society of Health-System Pharmacists. 2015년 12월 25일에 원본 문서에서 보존된 문서. 2015년 12월 1일에 확인함.
World Health Organization (2019). 《World Health Organization model list of essential medicines: 21st list 2019》. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). 《World Health Organization model list of essential medicines: 22nd list (2021)》. Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Sunagawa O, Shinzato Y, Touma T, Tomori M, Fukiyama K (May 2000). “Differences between coronary hyperresponsiveness to ergonovine and vasospastic angina”. 《Japanese Heart Journal》 41 (3): 257–268. doi:10.1536/jhj.41.257. PMID10987346.
Ott J, Neely P (1980). “Entheogenic (hallucinogenic) effects of methylergonovine”. 《Journal of Psychedelic Drugs》 12 (2): 165–166. doi:10.1080/02791072.1980.10471568. PMID7420432.
Cavero I, Guillon JM (2014). “Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy”. 《Journal of Pharmacological and Toxicological Methods》 69 (2): 150–161. doi:10.1016/j.vascn.2013.12.004. PMID24361689.